Rameen Kasana
2 min read
In This Article:
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at TD Cowen reaffirmed their Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), expressing confidence in the company’s mitapivat drug ahead of trial results.
The financial services firm believes that the drug will show considerable reductions in vaso-occlusive crises (VOCs) during the Phase 3 RISE-UP trial for sickle cell disease (SCD), with full results expected by the end of this year. With SCD’s sales potential of $4 billion, TD Cowen highlights the company’s position in this emerging market.
A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals.
The company was also named TD Cowen’s top small to mid-cap pick as it views positive Phase 3 trial results to be the turnaround point for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Having said that, the stock price could rise by as high as 100% by the year’s end. With the lead candidate FDA-approved and two more on the horizon, achieving the price target set by analysts doesn’t seem impossible.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company incorporated in 2007. This Massachusetts-based company engages in the discovery and development of treatments in the area of cellular metabolism. With PYRUKYND (mitapivat) as its lead candidate, the giant aims to elevate and extend the lives of many.
While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
